| pubmed-article:7387830 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7387830 | lifeskim:mentions | umls-concept:C0033477 | lld:lifeskim |
| pubmed-article:7387830 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
| pubmed-article:7387830 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:7387830 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:7387830 | lifeskim:mentions | umls-concept:C1446680 | lld:lifeskim |
| pubmed-article:7387830 | lifeskim:mentions | umls-concept:C0439064 | lld:lifeskim |
| pubmed-article:7387830 | lifeskim:mentions | umls-concept:C0205171 | lld:lifeskim |
| pubmed-article:7387830 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:7387830 | pubmed:dateCreated | 1980-9-28 | lld:pubmed |
| pubmed-article:7387830 | pubmed:abstractText | The murine dose of i.v. C. parvum (466 microgram) was compared with a single, low, human-equivalent dose of 70 microgram and with repeated weekly low doses. All treatments increased the antibody titre against C. parvum (CP). However, repeated doses stimulated a much higher titre than single doses. In all treated animals spleen weight peaked at 2 weeks and then fell. A single low dose caused a 3-fold increase, a single high dose or multiple low doses a 6-fold increase. Liver weight changes followed a similar pattern. Hepatosplenomegaly was prolonged by multiple doses. The effects of these treatments on Lewis tumour metastases were studied. A single high dose and a single low dose on the day of tumour implantation (Day 0) were equally effective at inhibiting pulmonary metastases. Repeated low doses starting on Day 0 were no more effective than a single dose. The effect of CP on survival after primary-tumour excision on Day 10 was observed. Low dose CP on Day 7 doubled the harmonic mean of survival time. Repeated doses were no more effective than a single dose. Low-dose prophylaxis up to 2 weeks before tumour significantly inhibited metastases. However, when repeated low-dose prophylaxis was combined with a single low dose on Day 0, the anti-metastatic effect was abrogated. This neutralization of the anti-metastatic effect of CP given on Day 0 was found to persist after a 13-week treatment-free interval. Possible mechanisms for this phenomenon are discussed. | lld:pubmed |
| pubmed-article:7387830 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7387830 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7387830 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7387830 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7387830 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7387830 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7387830 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7387830 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7387830 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7387830 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7387830 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7387830 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7387830 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7387830 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7387830 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7387830 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7387830 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7387830 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7387830 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7387830 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7387830 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7387830 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7387830 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7387830 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7387830 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7387830 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7387830 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7387830 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7387830 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7387830 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:7387830 | pubmed:issn | 0007-0920 | lld:pubmed |
| pubmed-article:7387830 | pubmed:author | pubmed-author:CastroJ EJE | lld:pubmed |
| pubmed-article:7387830 | pubmed:author | pubmed-author:SadlerT ETE | lld:pubmed |
| pubmed-article:7387830 | pubmed:author | pubmed-author:MitchesonH... | lld:pubmed |
| pubmed-article:7387830 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7387830 | pubmed:volume | 41 | lld:pubmed |
| pubmed-article:7387830 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7387830 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7387830 | pubmed:pagination | 407-14 | lld:pubmed |
| pubmed-article:7387830 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:7387830 | pubmed:meshHeading | pubmed-meshheading:7387830-... | lld:pubmed |
| pubmed-article:7387830 | pubmed:meshHeading | pubmed-meshheading:7387830-... | lld:pubmed |
| pubmed-article:7387830 | pubmed:meshHeading | pubmed-meshheading:7387830-... | lld:pubmed |
| pubmed-article:7387830 | pubmed:meshHeading | pubmed-meshheading:7387830-... | lld:pubmed |
| pubmed-article:7387830 | pubmed:meshHeading | pubmed-meshheading:7387830-... | lld:pubmed |
| pubmed-article:7387830 | pubmed:meshHeading | pubmed-meshheading:7387830-... | lld:pubmed |
| pubmed-article:7387830 | pubmed:meshHeading | pubmed-meshheading:7387830-... | lld:pubmed |
| pubmed-article:7387830 | pubmed:meshHeading | pubmed-meshheading:7387830-... | lld:pubmed |
| pubmed-article:7387830 | pubmed:meshHeading | pubmed-meshheading:7387830-... | lld:pubmed |
| pubmed-article:7387830 | pubmed:meshHeading | pubmed-meshheading:7387830-... | lld:pubmed |
| pubmed-article:7387830 | pubmed:meshHeading | pubmed-meshheading:7387830-... | lld:pubmed |
| pubmed-article:7387830 | pubmed:meshHeading | pubmed-meshheading:7387830-... | lld:pubmed |
| pubmed-article:7387830 | pubmed:meshHeading | pubmed-meshheading:7387830-... | lld:pubmed |
| pubmed-article:7387830 | pubmed:meshHeading | pubmed-meshheading:7387830-... | lld:pubmed |
| pubmed-article:7387830 | pubmed:year | 1980 | lld:pubmed |
| pubmed-article:7387830 | pubmed:articleTitle | Single versus multiple human-equivalent doses of C. parvum in mice: neutralization of the anti-metastatic effect. | lld:pubmed |
| pubmed-article:7387830 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7387830 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7387830 | lld:pubmed |
